Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The beta-2 subunit-containing nicotinic acetylcholine receptor (β2-nAChR), often referred to as the α4β2 nAChR when paired with the alpha-4 subunit, is a member of the Cys-loop superfamily of ligand-gated ion channels. These receptors are pentameric complexes composed of five transmembrane subunits. The β2 subunit is one of four known neuronal β-type nAChR subunits in mammals. They mediate fast synaptic transmission by allowing cation influx upon activation by acetylcholine or exogenous ligands such as nicotine, playing key roles in neurotransmitter release, synaptic plasticity, attention, learning, memory, and reward pathways. Alterations in expression or function of β2-containing nAChRs have been implicated in cognitive disorders, neurodegenerative diseases, and epilepsy.
Agonist binding leading to cation channel opening and neuronal depolarization
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Beta-2 Subunit-Containing Nicotinic Acetylcholine Receptor (β2-nAChR).